Dysregulation of the Ras/Raf/MEK/ERK signaling pathway (also known as the mitogen-activated protein [MAP] kinase pathway) has been implicated in many types of cancer, including melanoma, pancreas, colon and lung cancer, and this pathway has become an attractive target for therapeutic development. There has been some success in targeting Raf, but previously developed MEK inhibitors have yielded limited clinical benefit. This review focuses on the preclinical and clinical development of trametinib dimethyl sulfoxide (GSK-1120212B), a selective MEK 1/2 inhibitor.
- MAP kinase kinase inhibitor
- Signaling pathway
- Trametinib dimethyl sulfoxide
ASJC Scopus subject areas
- Pharmacology (medical)